1. Home
  2. BANX vs ALXO Comparison

BANX vs ALXO Comparison

Compare BANX & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BANX

ArrowMark Financial Corp.

HOLD

Current Price

$20.42

Market Cap

191.0M

Sector

Finance

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$1.91

Market Cap

205.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BANX
ALXO
Founded
N/A
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
191.0M
205.9M
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
BANX
ALXO
Price
$20.42
$1.91
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$3.50
AVG Volume (30 Days)
31.6K
741.2K
Earning Date
01-01-0001
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
26.36
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$18.45
$0.60
52 Week High
$23.67
$2.66

Technical Indicators

Market Signals
Indicator
BANX
ALXO
Relative Strength Index (RSI) 66.23 47.21
Support Level $19.33 $1.37
Resistance Level $21.65 $2.27
Average True Range (ATR) 0.24 0.13
MACD 0.05 -0.02
Stochastic Oscillator 89.52 25.81

Price Performance

Historical Comparison
BANX
ALXO

About BANX ArrowMark Financial Corp.

ArrowMark Financial Corp is a non-diversified, closed-end management investment company. The Fund's objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds and others.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: